For example, patient 8 showed a pathogenic variant in NRAS and in WT1. Pathogenic variants in NRAS occur in ~12% of all AML cases and co-occur with pathogenic variants in epigenetic modifiers (TET2/IDH/WT1). This evidence concerns the gene TET2 and acute myeloid leukemia.